HIV/AIDS NDAs For Fixed-Dose Combination Will Be Exempt From User Fees
This article was originally published in The Pink Sheet Daily
Executive Summary
Expedited FDA review process for combination antiretroviral drugs announced at World Health Organization meeting. Generic versions of patented medicines would receive a “tentative” approval and be eligible for use in the Administration’s $15 bil. assistance program.
You may also be interested in...
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.